Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William Faquin

Showing results (11-20 of 97) with videos related to

Pageof 10
Sort By:
Cancer Cytopathology|May 5, 2026
Funding cuts and mixed messages threaten the rise of mRNA vaccine technology: Researchers express deep concern over cuts to the vaccine science that could boost cancer immunotherapyBryn Nelson, William Faquin
Cancer Cytopathology|July 1, 2026
New progress in addressing cancer pain: Recent studies have offered revealing insights into predisposing, precipitating, and perpetuating factors as well as underlying mechanisms and potential interventionsBryn Nelson, William Faquin
Cancer Cytopathology|November 8, 2022
The fall of Roe and the growing fallout for medical care: As shown in this second part of a two-part series, a flurry of new antiabortion laws has demonstrated how biopolitical decisions can create spillover effects in unanticipated and unintended areas of medicine and quickly sow fear and confusion over standards of care: As shown in this second part of a two-part series, a flurry of new antiabortion laws has demonstrated how biopolitical decisions can create spillover effects in unanticipated and unintended areas of medicine and quickly sow fear and confusion over standards of careBryn Nelson, William Faquin
Cancer Cytopathology|November 1, 2023
The unexpected costs of "free" preventive care: In this first of a two-part series on the struggle to balance preventive care costs and benefits, federal laws have directed insurers to offer free cancer screens, but loopholes and uneven implementation have left many consumers holding the bagBryn Nelson, William Faquin
Cancer Cytopathology|January 2, 2024
Generic cancer drugs are still in short supply: The ongoing shortage has forced hospitals to continue rationing drugs and prompted new calls for federal investment and long-term solutionsBryn Nelson, William Faquin
Cancer Cytopathology|November 17, 2024
Retrieving new clues about a dog breed's "insane" cancer risk: In this second of a two-part series on what we can learn from unusually cancer-resistant or -susceptible animals, research digging into remarkably high cancer mortality rates for golden retrievers has revealed some intriguing new insightsBryn Nelson, William Faquin
Cancer Cytopathology|May 3, 2025
Repurposed drugs may lend a new hand as add-ons to existing cancer treatments: Recent studies suggest that some drugs may act via secondary mechanisms to achieve additive or synergistic anti-cancer effectsBryn Nelson, William Faquin
Cancer Cytopathology|February 4, 2026
Disappearing act: The US retreat on research funding is dimming the future of international cancer research: In this second of a three-part series on how new US policies and funding cuts are affecting cancer research, scientists warn that restrictive funding policies may turn off key partnershipsBryn Nelson, William Faquin
Cancer Cytopathology|April 3, 2025
How pro-inflammatory diets may create the right recipe for cancer: In this second of a two-part series on how nutrition can influence cancer, recent studies linking some foods and additives to higher cancer risks have zeroed in on the contributing role of unresolved inflammationBryn Nelson, William Faquin
Cancer Cytopathology|May 4, 2023
Breaking free of the research silo: A growing case for multidisciplinary work: From studying human origins to developing cancer diagnoses and treatments, working across disciplines is not always easy, but it is often transformative: From studying human origins to developing cancer diagnoses and treatments, working across disciplines is not always easy, but it is often transformativeBryn Nelson, William Faquin
Pageof 10

Showing results (11-20 of 97) with videos related to

Sort By:
Pageof 10
Cancer Cytopathology|May 5, 2026
Funding cuts and mixed messages threaten the rise of mRNA vaccine technology: Researchers express deep concern over cuts to the vaccine science that could boost cancer immunotherapyBryn Nelson, William Faquin
Cancer Cytopathology|July 1, 2026
New progress in addressing cancer pain: Recent studies have offered revealing insights into predisposing, precipitating, and perpetuating factors as well as underlying mechanisms and potential interventionsBryn Nelson, William Faquin
Cancer Cytopathology|November 8, 2022
The fall of Roe and the growing fallout for medical care: As shown in this second part of a two-part series, a flurry of new antiabortion laws has demonstrated how biopolitical decisions can create spillover effects in unanticipated and unintended areas of medicine and quickly sow fear and confusion over standards of care: As shown in this second part of a two-part series, a flurry of new antiabortion laws has demonstrated how biopolitical decisions can create spillover effects in unanticipated and unintended areas of medicine and quickly sow fear and confusion over standards of careBryn Nelson, William Faquin
Cancer Cytopathology|November 1, 2023
The unexpected costs of "free" preventive care: In this first of a two-part series on the struggle to balance preventive care costs and benefits, federal laws have directed insurers to offer free cancer screens, but loopholes and uneven implementation have left many consumers holding the bagBryn Nelson, William Faquin
Cancer Cytopathology|January 2, 2024
Generic cancer drugs are still in short supply: The ongoing shortage has forced hospitals to continue rationing drugs and prompted new calls for federal investment and long-term solutionsBryn Nelson, William Faquin
Cancer Cytopathology|November 17, 2024
Retrieving new clues about a dog breed's "insane" cancer risk: In this second of a two-part series on what we can learn from unusually cancer-resistant or -susceptible animals, research digging into remarkably high cancer mortality rates for golden retrievers has revealed some intriguing new insightsBryn Nelson, William Faquin
Cancer Cytopathology|May 3, 2025
Repurposed drugs may lend a new hand as add-ons to existing cancer treatments: Recent studies suggest that some drugs may act via secondary mechanisms to achieve additive or synergistic anti-cancer effectsBryn Nelson, William Faquin
Cancer Cytopathology|February 4, 2026
Disappearing act: The US retreat on research funding is dimming the future of international cancer research: In this second of a three-part series on how new US policies and funding cuts are affecting cancer research, scientists warn that restrictive funding policies may turn off key partnershipsBryn Nelson, William Faquin
Cancer Cytopathology|April 3, 2025
How pro-inflammatory diets may create the right recipe for cancer: In this second of a two-part series on how nutrition can influence cancer, recent studies linking some foods and additives to higher cancer risks have zeroed in on the contributing role of unresolved inflammationBryn Nelson, William Faquin
Cancer Cytopathology|May 4, 2023
Breaking free of the research silo: A growing case for multidisciplinary work: From studying human origins to developing cancer diagnoses and treatments, working across disciplines is not always easy, but it is often transformative: From studying human origins to developing cancer diagnoses and treatments, working across disciplines is not always easy, but it is often transformativeBryn Nelson, William Faquin
Pageof 10